



Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/666,191
Filing Date	September 17, 2003
First Named Inventor	Laszlo Prokai
Art Unit	1614
Examiner Name	

Sheet	1	of	3	Attorney Docket Number	UF-300XC2
-------	---	----	---	------------------------	-----------

U.S. PATENT DOCUMENTS

/Barbara Badio/

12/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

BEST AVAILABLE COPY



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/666,191
				Filing Date	September 17, 2003
				First Named Inventor	Laszlo Prokai
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	UF-300XC2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
BB	R1	BREUER, H. and KOSTER, G. (1974) "Interaction Between Oestrogens and Neurotransmitters at the Hypophysial-Hypothalamic Level." <i>Journal of Steroid Biochemistry</i> . Vol. 5, pp. 961-967.		
	R2	GALDECKI, Z., P. et al. (1987) "Structure of 2,4-Dibromo-10 β , 17 β -dihydroxy-1,4-estradien-3-one" <i>Acta Cryst.</i> Vol. c43, pages 967-968.		
	R3	HIEMKE, C. et al. (1992) "Actions of Sex Hormones on the Brain." <i>Prog. Neuro-Psychopharmacol. & Biol.Psychiat.</i> Vol. 16, pp. 377-388.		
	R4	KUPFER, RENE, LONG YU LIU, ALBAN J. ALLENTOFF, JOHN A. THOMPSON (2001) "Comparisons of Hydroperoxide Isomerase and Monooxygenase Activities of Cytochrome P450 for Conversions of Allylic Hydroperoxides and Alcohols to Epoxyalcohols and Diols: Probing Substrate Reorientation in the Active Site" <i>Biochemistry</i> 40:11490-11501.		
	R5	LIANG, Y. et al. (2001) "Membrane fluidity effects of estratrienes." <i>Brain Research Bulletin</i> . Vol. 54, No. 6, pp. 661-668.		
	R6	MCCULLOUGH, LOUISE D. and PATRICIA D. HURN (July 2003) "Estrogen and Ischemic Neuroprotection: an integrated view" <i>Trends in Endocrinology and Metabolism</i> 14(5):228-235.		
	R7	MILIC, D. et al.(1999) "X-Ray Crystal Structure of 10 β -Hydroxy-4 β ,5 β -epoxyestr-1-en-3,17-dione and Antitumor Activity of its Congeners" <i>Molecules</i> , Vol. 4, pp.338-352.		
	R8	MILIC, D. et al. (1997) "The Synthesis and Biological Evaluation of A-Ring Substituted Steroidal <i>p</i> -Quinones" <i>Tetrahedron</i> , Vol. 53, No. 41, pp. 14073-14084.		
	R9	MILIC, D. et al. (1997) "Structure and Reactivity of Steroidal Quinones" <i>J. Serb. Chem. Soc.</i> , Vol. 62, No. 9, pp. 755-768.		
	R10	NILSEN, J. and BRINTON, D. (2003) "Divergent Impact of Progesterone and Medroxyprogesterone Acetate (Provera) on Nuclear Mitogen-activated Protein Kinase Signaling." Vol. 100, No. 18, pp.10506-10511.		
	R11	NILSEN, JON and ROBERTA DIAZ BRINTON (January 2002) "Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate" <i>Endocrinology</i> 143(1):205-212.		
BB	R12	NUMAZAWA, MITSUTERU, KUMIKO HOSHI, KATSUHIKO KIMURA (1989) "Oxygenation of 2,4-Dibromoestrogens with Nitric Acid: A New Synthesis of 19-Nor Steroids" <i>Chem. Pharm Bull.</i> 37(8):2058-2062.		

Examiner Signature	/Barbara Badio/	Date Considered	12/12/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached, his collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/666,191
Filing Date	September 17, 2003
First Named Inventor	Laszlo Prokai
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	UF-300XC2

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BB	R1	OHE, TOMOYUKI, MASAOKI HIROBE, TADAHIKO MASHINO (2000) "Novel Metabolic Pathway of Estrone and 17 β -Estradiol Catalyzed by Cytochrome P-450" <i>Drug Metabolism and Disposition</i> 28(2):110-112.	
	R2	PROKAI, K. et al. (2003) "Modifying Peptide Properties by Prodrug Design For Enhanced Transport into CNS." <i>Progress in Drug Research</i> , Vol. 61, pp. 158-188.	
	R3	PROKAI, L. et al. (2003) "Quinol-based Cyclic Antioxidant Mechanism in Estrogen Neuroprotection" <i>PNAS</i> , Vol. 100 No. 20, pp. 11741-11746.	
	R4	PROKAI, L. et al. (2003) "Short Communication: Quinol-Based Metabolic Cycle For Estrogens in Rat Liver Microsomes" <i>Drug and Metabolism and Disposition</i> , Vol. 31, No. 6, pp. 701-704.	
	R5	PROKAI, L. et al. (2001) "Synthesis and Biological Evaluation of 17 β -Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress" <i>J. Med. Chem.</i> , Vol. 44, pp. 110-114.	
	R6	PROKAI, L., et al. (2000) "Targeting Drugs to the Brain by Redox Chemical Delivery Systems" <i>Med. Res. Rev.</i> , Vol. 20, No. 5, pp. 367-416.	
BB	R7	SOLAJA, B. et al. (1996) "A Novel <i>m</i> -CPBA Oxidation: <i>p</i> -Quinols and Epoxyquinols from Phenols" <i>Tetrahedron Letters</i> , Vol. 37, No. 21, pp. 3765-3768.	
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner
Signature


/Barbara Badio/

Date

Considered

12/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. his collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/666,191
Filing Date	09/17/2003
First Named Inventor	Laszlo Prokai
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	UF-300XC2

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
BB	U1	US- 5,891,878	04-06-1999	Beasley <i>et al.</i>	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner
Signature

/Barbara Badio/

Date
Considered

12/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	10/405,413	
			Filing Date	April 2, 2003	
			First Named Inventor	Laszlo Prokai	
			Art Unit	1614	
			Examiner Name	Not yet assigned	
Sheet	1	of	2	Attorney Docket Number	UF-300XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BB	U1	US-2,910,486 A	10-27-1959	James Jiu	
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
BB	F1	WO 03/084978 A	10-16-2003	University of Florida		
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	/Barbara Badio/	Date Considered	12/12/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/496,413
Filing Date	April 2, 2003
First Named Inventor	Laszlo Prokai
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	UF-300XC1

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BB	R1	BEERS, M.H. and R. BERKOW, Editors, The Merck Manual of diagnosis and therapy, pages 471-473 and pages 1942-1944 (1999) Merck Research Laboratories, Whitehouse Station, N.J. USA.	
BB	R2	LUPON, P. et al. (1983) "Photooxygenierung von Oestrogenen: Eine Neu 19-Norsteroid-Synthese" Verlagsgesellschaft, Weinheim, DE, Vol. 95, No. 9, page 757.	
BB	R3	SEDEE, A.G. J. et al. (1983) ^{synthesis} "A synthesis for p-quinol compounds from phenols fused with other saturated rings" Tetrahedron Letters 24(51):5779-5780.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	/Barbara Badio/	Date Considered	12/12/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/666,191
				Filing Date	September 17, 2003
				First Named Inventor	Laszlo Prokai
				Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	1	of	1	Attorney Docket Number	UF-300XC2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BB	U1	US 2003/0050295 A1	03-13-2003	Iok-Hou Pang	All
BB	U2	US 2003/0105167 A1	06-05-2003	James Alan Dykens	All
BB	U3	US 2004/0214806 A1	10-28-2004	Iok-Hou Pang	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1		
	R2		
	R3		
	R4		

Examiner Signature	/Barbara Badio/	Date Considered	12/12/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.